Last reviewed · How we verify
EndoTAG-1 and Gemcitabine
EndoTAG-1 is a peptide that targets the tumor vasculature, while Gemcitabine is a nucleoside analog that interferes with DNA synthesis.
EndoTAG-1 is a peptide that targets the tumor vasculature, while Gemcitabine is a nucleoside analog that interferes with DNA synthesis. Used for Pancreatic cancer.
At a glance
| Generic name | EndoTAG-1 and Gemcitabine |
|---|---|
| Sponsor | MediGene |
| Drug class | Peptide |
| Target | Tumor vasculature |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
EndoTAG-1 selectively binds to the tumor vasculature, causing damage to the endothelial cells and disrupting tumor blood supply. Gemcitabine, on the other hand, is a prodrug that is converted into its active form, which is then incorporated into DNA, causing DNA strand breaks and inhibiting DNA synthesis, leading to cell death.
Approved indications
- Pancreatic cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX (PHASE3)
- A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer (PHASE3)
- EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EndoTAG-1 and Gemcitabine CI brief — competitive landscape report
- EndoTAG-1 and Gemcitabine updates RSS · CI watch RSS
- MediGene portfolio CI